Genus/£GNS
1D1W1MYTD1Y5YMAX
Capital at risk
About Genus
Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.
- Ticker
- £GNS
- Sector
- Health
- Primary listing
- LSE
- Employees
- 3,190
- Headquarters
- Basingstoke, United Kingdom
- Website
- www.genusplc.com
Genus Metrics
BasicAdvanced
£1.4B
5.06
£4.25
0.90
£0.33
1.53%
Price and volume
Market cap
£1.4B
Beta
0.9
52-week high
£32.20
52-week low
£19.43
Average daily volume
204K
Dividend rate
£0.33
Financial strength
Current ratio
2.215
Quick ratio
1.419
Long term debt to equity
0.122
Total debt to equity
0.14
Dividend payout ratio (TTM)
7.61%
Interest coverage (TTM)
3.80%
Profitability
EBITDA (TTM)
103.5
Gross margin (TTM)
100.00%
Net profit margin (TTM)
43.35%
Operating margin (TTM)
12.14%
Effective tax rate (TTM)
8.05%
Revenue per employee (TTM)
£210,000
Management effectiveness
Return on assets (TTM)
5.21%
Return on equity (TTM)
45.95%
Valuation
Price to earnings (TTM)
5.062
Price to revenue (TTM)
2.162
Price to book
1.85
Price to tangible book (TTM)
2.31
Price to free cash flow (TTM)
25.268
Free cash flow yield (TTM)
3.96%
Free cash flow per share (TTM)
0.852
Dividend yield (TTM)
1.53%
Growth
Revenue change (TTM)
-2.18%
Earnings per share change (TTM)
1,370.93%
3-year revenue growth (CAGR)
-1.55%
10-year revenue growth (CAGR)
5.42%
3-year earnings per share growth (CAGR)
103.42%
10-year earnings per share growth (CAGR)
18.13%
3-year dividend per share growth (CAGR)
3.23%
10-year dividend per share growth (CAGR)
5.10%
What the Analysts think about Genus
Analyst ratings (Buy, Hold, Sell) for Genus stock.
Analyst projections of the future price of Genus stock.
Bulls say / Bears say
Genus expects FY26 adjusted profit before tax of approximately £98m, moderately ahead of consensus, with strong second-half trading led by PIC growth in Asia and Latin America. (LSE RNS)
The Chinese porcine joint venture delivered approximately £111m of net cash consideration, reducing expected year-end net leverage to around 0.4x and materially strengthening Genus’s balance sheet for FY27 investment and resilience. (LSE RNS)
Genus is broadening its biotechnology pipeline through an August 2026 collaboration with Tropic Biosciences to explore gene-silencing applications across porcine and bovine genetics, potentially expanding its differentiated product portfolio. (Genus)
FY26 performance remained exposed to livestock-cycle volatility: Genus reported weaker North American PIC trading because of customer disease challenges, while ABS faced softer demand and adverse product mix from lower global dairy prices. (LSE RNS)
The approximately £98m FY26 adjusted profit-before-tax outlook includes a £5.6m milestone payment from Beijing Capital Agribusiness, meaning reported earnings are partly supported by a non-recurring contribution and may overstate underlying operating momentum. (LSE RNS)
The investment case still depends on successful commercialization and regulatory progress for gene-editing and reproductive technologies; Genus’s new Tropic Biosciences collaboration is exploratory, so the timing and financial payoff remain uncertain. (Genus)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Genus Financial Performance
Revenues and expenses
Genus Earnings Performance
Company profitability
Upcoming events
Funds containing Genus
AllGBPEURUSD
Fund name | Fund size | £GNS weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.48% |
iShares FTSE 250£MIDD | £661M | 0.47% |
iShares Agribusiness€ISAE | €512M | 0.44% |
iShares Agribusiness£SPAG | £439M | 0.44% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.13% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.